Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
Alirocumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
alirocumab: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
CDK14 MCP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for CDK14, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Rezpegaldesleukin Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
rezpegaldesleukin: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Cladribine Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
cladribine: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Efmoroctocog alfa(Sobi Analytics) Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
efmoroctocog alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Mitapivat Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
mitapivat: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Ecopipam Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
ecopipam: Phase 3. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Efanesoctocog alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
efanesoctocog alfa: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
8 min read
CDK13 MCP Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
16 July 2026
A visual target evaluation report for CDK13, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Hydroxycarbamide Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
hydroxyurea: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Daxdilimab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
daxdilimab: Phase 2. 2026 diligence verdict: CONDITIONAL GO. Evidence review covers clinical, IP, deals, and risks.
Latest Hotspot
8 min read
Mavrilimumab Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
16 July 2026
mavrilimumab: Discontinued. 2026 diligence verdict: HOLD / OPTION. Evidence review covers clinical, IP, deals, and risks.